Xtx Topco LTD Xencor Inc Transaction History

Xtx Topco LTD

  • $2.23 Billion
  • Q2 2025

A detailed history of Xtx Topco LTD transactions in Xencor Inc stock. As of the latest transaction made, Xtx Topco LTD holds 33,230 shares of XNCR stock, worth $399,756. This represents 0.01% of its overall portfolio holdings.

Number of Shares
33,230
Previous 54,209 38.7%
Holding current value
$399,756
Previous $576,000 54.69%
% of portfolio
0.01%
Previous 0.03%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
SELL
$7.52 - $11.26 $157,762 - $236,223
-20,979 Reduced 38.7%
33,230 $261,000
Q1 2025

May 07, 2025
BUY
$10.64 - $24.13 $379,071 - $859,679
35,627 Added 191.73%
54,209 $576,000
Q4 2024

Feb 13, 2025
SELL
$19.43 - $26.84 $67,966 - $93,886
-3,498 Reduced 15.84%
18,582 $427,000
Q3 2024

Nov 14, 2024
BUY
$15.7 - $21.65 $184,082 - $253,846
11,725 Added 113.23%
22,080 $444,000
Q2 2024

Aug 12, 2024
BUY
$18.21 - $24.5 $188,564 - $253,697
10,355 New
10,355 $196,000
Q3 2023

Nov 13, 2023
BUY
$20.08 - $25.39 $230,618 - $291,604
11,485 Added 89.73%
24,285 $489,000
Q2 2023

Aug 14, 2023
BUY
$24.77 - $29.9 $317,056 - $382,720
12,800 New
12,800 $319,000
Q4 2022

Feb 14, 2023
BUY
$24.79 - $30.86 $42,787 - $53,264
1,726 Added 15.91%
12,572 $327,000
Q3 2022

Nov 14, 2022
BUY
$24.62 - $32.44 $267,028 - $351,844
10,846 New
10,846 $282,000
Q3 2021

Nov 12, 2021
SELL
$30.65 - $35.68 $188,742 - $219,717
-6,158 Closed
0 $0
Q2 2021

Aug 12, 2021
BUY
$34.33 - $44.68 $211,404 - $275,139
6,158 New
6,158 $212,000

Others Institutions Holding XNCR

# of Institutions
204
Shares Held
81.9M
Call Options Held
0
Put Options Held
0
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $718M
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Xtx Topco LTD Portfolio

Follow Xtx Topco LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email